List of Excipients in Branded Drug XENON, XE-133

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Curium US LLC	XENON, XE-133	xenon	69945-097	AIR

XENON Xe-133 Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Xenon Xe-133 is a radioactive diagnostic gas used primarily for pulmonary ventilation imaging and, in selected settings, cerebral blood-flow studies. Its commercial value does not depend on conventional excipients. The product is an inhaled radionuclide supplied in a controlled gas presentation, so the key commercial levers are radiochemical purity, dose calibration, container closure, administration equipment, radiation safety, distribution reliability, and workflow integration.

What is XENON Xe-133 used for?

Xenon Xe-133 is an inhaled radiopharmaceutical. Its principal clinical use is evaluation of pulmonary ventilation. It has also been used for cerebral blood-flow assessment and other nuclear-medicine imaging applications, although clinical utilization varies by institution and competing imaging modalities.

Attribute	XENON Xe-133
Active substance	Xenon-133 radioactive isotope
Dosage form	Inhalation gas
Administration route	Pulmonary inhalation
Primary use	Pulmonary ventilation imaging
Radiation type	Beta and gamma emissions
Physical half-life	Approximately 5.2 days
Product category	Diagnostic radiopharmaceutical
Conventional excipients	Generally absent or functionally limited
Main technical controls	Activity concentration, radionuclidic identity, purity, container integrity, delivery accuracy
Main competitors	Technetium-99m ventilation agents, krypton-81m where available, CT and MRI-based alternatives

The FDA-approved labeling for Xenon Xe-133 identifies pulmonary ventilation evaluation as the principal indication and describes administration through an inhalation system or equivalent delivery apparatus.[1]

What excipients are used in Xenon Xe-133 products?

Xenon Xe-133 has little conventional excipient demand because the active ingredient is itself a gas administered by inhalation. Unlike tablets, injectables, suspensions, or biologics, the product does not require a stabilizing matrix, solubilizer, preservative, buffer, surfactant, or release-modifying polymer.

Functional composition of the product

A commercial Xe-133 presentation may include:

1. Xenon-133 as the radioactive active ingredient.
2. A carrier or diluent gas, depending on the manufacturer’s presentation and administration system.
3. A validated container, vial, canister, or delivery bag.
4. A transfer or inhalation interface.
5. Shielding and labeling components required for radioactive materials.

The carrier gas is better analyzed as a formulation or delivery component than as a traditional pharmaceutical excipient. Its role may include facilitating transfer, maintaining a usable gas volume, supporting inhalation, or enabling dilution to a clinically appropriate activity concentration.

The product-specific package insert and certificate of analysis control the applicable composition. A carrier gas cannot be assumed to be interchangeable across manufacturers because gas composition, container pressure, activity concentration, and administration hardware can affect dose delivery and operational compliance.

Why traditional excipient optimization has limited value

Traditional excipient strategies target chemical stability, dissolution, absorption, taste, viscosity, preservative protection, or controlled release. Those objectives have limited relevance to Xe-133 because:

• The isotope decays by radioactive transformation rather than conventional chemical degradation.
• The product is delivered as a gas rather than a solid or liquid dosage form.
• The effective shelf life is governed primarily by radioactive decay and logistics.
• The isotope does not require a solubilization strategy.
• Pulmonary delivery depends more on breathing protocol and equipment than on excipient-mediated absorption.

The commercial opportunity therefore lies in the product system surrounding Xe-133, not in a new excipient composition.

What excipient patents could protect a Xenon Xe-133 product?

Few conventional excipient patent claims would provide meaningful protection for Xe-133. A patent directed only to a carrier gas or inert diluent would likely face substantial validity and freedom-to-operate challenges unless it produced a specific, demonstrated improvement in dose uniformity, aerosol behavior, container stability, radiation safety, or clinical workflow.

More commercially relevant claim categories include:

Gas composition and dose uniformity

A formulation patent could cover a defined xenon-to-carrier-gas ratio, pressure range, activity concentration, or gas homogeneity specification. Such claims would need to establish a technical benefit, such as:

• More reproducible delivered activity.
• Reduced segregation or adsorption.
• Improved transfer from production container to inhalation apparatus.
• Lower residual activity in the delivery system.
• Better reproducibility across patient breathing patterns.

Broad claims to "Xe-133 with an inert gas" would likely be vulnerable to prior-art objections unless supported by a specific performance advantage.

Container-closure and packaging systems

Packaging is a stronger patent and commercial area than excipient composition. Potentially protectable features include:

• Low-permeability containers.
• Radiation-compatible elastomers.
• Reduced adsorption of xenon onto internal surfaces.
• Pressure-control mechanisms.
• Metered-dose transfer assemblies.
• Shielded single-use administration packages.
• Integrated decay and activity labeling.
• Tamper-evident radioactive-material containers.

The patent value would arise from maintaining calibrated activity and reducing operational losses rather than from the carrier gas itself.

Administration devices

A device patent could cover a closed-loop system that controls inhaled activity, minimizes room contamination, or improves patient dosimetry. Relevant features may include:

• Rebreathing circuits.
• Scavenging systems.
• Respiratory-phase synchronization.
• Automated wash-in and wash-out control.
• Activity monitoring during inhalation.
• Breath-hold or ventilation-protocol guidance.
• Connection systems that prevent incorrect transfer.

These technologies can create a defensible commercial position even when the underlying Xe-133 molecule is old and unpatentable.

What is the FDA regulatory status of Xenon Xe-133?

Xenon Xe-133 is an FDA-regulated diagnostic radiopharmaceutical. The approved product labeling identifies the drug as Xenon Xe-133 Gas and describes inhalational administration for pulmonary ventilation studies.[1]

The regulatory framework includes:

• FDA approval of the drug product.
• Current Good Manufacturing Practice requirements.
• Radioactive-material licensing.
• State or Nuclear Regulatory Commission controls.
• Quality testing for identity, activity, radionuclidic purity, and container integrity.
• Specialized shipping and handling requirements.

Radiopharmaceutical products also face a practical distinction between drug approval and radioactive-material authorization. A manufacturer may need both an FDA-compliant drug manufacturing process and the applicable NRC or Agreement State approvals for possession, handling, and distribution of radioactive material.[2]

Is Xe-133 an Orange Book patent opportunity?

The Orange Book remains relevant for approved drug products and listed patents, but the commercial protection profile of Xe-133 is different from that of a newly launched small molecule.

The active isotope is not a realistic long-term composition-of-matter asset. Any remaining protection would more likely relate to:

• A specific formulation.
• A gas-generation or purification method.
• A container system.
• A delivery device.
• A method of use.
• A combination diagnostic protocol.

Patent status must be assessed against the current FDA Orange Book, product-specific labeling, and applicable patent databases. Regulatory exclusivity and patent exclusivity should not be treated as equivalent. The age of the active isotope and the existence of an approved product generally limit the ability to obtain broad new-drug exclusivity for the same diagnostic use.

When does Xenon Xe-133 lose exclusivity?

Xenon Xe-133 does not have a conventional high-value exclusivity profile comparable to a recently approved branded drug. Its principal commercial barriers are manufacturing, radioactive-material licensing, supply-chain execution, and hospital workflow adoption.

Exclusivity timeline

Protection category	Commercial relevance for Xe-133
Composition-of-matter patent	Minimal for the isotope itself
New chemical entity exclusivity	Not a practical basis for the mature product
Formulation patent	Possible but likely narrow
Device patent	Potentially meaningful
Manufacturing patent	Potentially meaningful if purification or packaging is differentiated
Method-of-use patent	Possible for a defined clinical protocol
Orphan exclusivity	Generally not the primary commercial framework
Generic or alternative-source entry	Constrained by radioactive production and distribution requirements

The relevant "loss of exclusivity" event is therefore less likely to be a single patent-expiration date and more likely to be the arrival of a qualified competing supplier, alternative radiopharmaceutical, or substitute imaging technology.

Which companies compete with Xenon Xe-133?

Competition comes from both radiopharmaceutical suppliers and non-radioactive imaging technologies.

Radiopharmaceutical competition

The principal nuclear-medicine alternative is technetium-99m-based pulmonary ventilation imaging, including aerosolized or gas-based formulations. Technetium-99m products may offer different equipment requirements, imaging characteristics, and supply-chain economics.

Krypton-81m is another ventilation agent in markets where availability and generator infrastructure support its use. Its very short half-life can provide efficient ventilation imaging but requires specialized supply arrangements.

Non-radioactive competition

Xe-133 also competes indirectly with:

• CT pulmonary angiography and high-resolution CT.
• MRI-based pulmonary imaging.
• Conventional radiography.
• Pulmonary-function testing.
• SPECT and hybrid imaging protocols.
• Bedside respiratory assessments.

The competitive choice depends on the clinical question. Xe-133 is most commercially viable where nuclear-medicine infrastructure already exists, pulmonary ventilation information is required, and the institution can manage radioactive gas safely.

What are the strongest commercial opportunities around Xe-133?

1. Closed-system delivery

A closed inhalation and scavenging system can reduce contamination risk, simplify staff procedures, and improve compliance with radiation-safety requirements. This is likely a more attractive commercial opportunity than a novel carrier gas.

Revenue could come from:

• Capital equipment.
• Disposable breathing circuits.
• Service contracts.
• Calibration and quality-control programs.
• Consumable transfer components.

2. Single-use calibrated dose packages

Precalibrated, patient-specific or study-specific packages could reduce preparation time and dosing errors. A commercial system could combine:

• Activity calibration.
• Expiration and decay data.
• Dose identification.
• Barcode or RFID tracking.
• Shielded transport.
• Administration instructions.

The system would target nuclear-medicine departments seeking lower handling burden and more consistent throughput.

3. Radiation-safe packaging

Packaging that limits leakage, improves shielding, and preserves gas integrity can address both regulatory and operational pain points. This opportunity is particularly relevant for regional distribution, where decay during transport reduces usable activity.

4. Workflow software

Software can calculate decay-adjusted activity, track delivery timing, document patient exposure, and generate quality records. Software alone may have limited pricing power, but it can increase the value of a hardware and consumables platform.

5. Alternative ventilation protocols

A sponsor could seek protection for a defined Xe-133 imaging protocol that improves interpretation, reduces administered activity, or supports a specific patient population. Such claims would require clinical evidence and would face method-of-use patentability and obviousness challenges.

What manufacturing and intellectual-property barriers affect Xe-133?

The main barriers are technical and regulatory rather than excipient-related.

Radioisotope production

Xe-133 is generally obtained through nuclear fission-product recovery or other specialized isotope-production processes. Production requires licensed nuclear facilities, radiochemical purification, quality testing, and a distribution network capable of managing short radioactive shelf life.

Decay and inventory management

With a half-life of approximately 5.2 days, inventory loses activity continuously. Manufacturers must coordinate:

• Production scheduling.
• Calibration time.
• Shipment timing.
• Hospital receipt and use.
• Replacement or credit policies.
• Activity reconciliation.

This creates a barrier to entry because a nominally inexpensive product can become commercially unattractive if delivery is delayed or demand is uneven.

Quality control

Relevant quality attributes include:

• Radionuclidic identity.
• Radionuclidic purity.
• Activity concentration.
• Gas composition.
• Container integrity.
• Absence of unacceptable contaminants.
• Accurate labeling at calibration time.
• Delivery-system compatibility.

Patent barriers

Potential patent barriers may cover:

• Isotope recovery and purification.
• Gas transfer systems.
• Container materials.
• Scavenging apparatus.
• Dose calibration.
• Imaging protocols.
• Integrated nuclear-medicine systems.

A freedom-to-operate review should separate patents covering Xe-133 itself from patents covering the delivery platform. The latter are more likely to remain commercially relevant.

How does Xe-133 compare with technetium-99m ventilation products?

Factor	Xe-133	Technetium-99m ventilation products
Physical form	Gas	Aerosol or gas, depending on product
Primary delivery challenge	Controlled inhalation and scavenging	Aerosol generation and particle deposition
Supply model	Radioactive gas production and distribution	Generator or radiopharmaceutical supply chain
Shelf-life pressure	Significant because of 5.2-day half-life	Also significant, depending on formulation and isotope
Excipient opportunity	Very limited	Greater opportunity for formulation and aerosol engineering
Device opportunity	High	High
Hospital infrastructure	Nuclear medicine and gas-handling controls	Nuclear medicine and aerosol-delivery equipment
Main differentiation	Ventilation distribution, workflow, dose handling	Aerosol performance, imaging quality, availability, workflow
Patent strategy	Device, packaging, process, method	Formulation, aerosol, device, method, manufacturing

Xe-133 may be attractive where gas administration is operationally established. Technetium-99m products may be more attractive for companies seeking formulation or aerosol-engineering IP.

What generic entry risks exist for Xenon Xe-133?

Generic entry risk is unusual because the product is a radioactive diagnostic gas rather than a conventional oral or injectable medicine.

The principal risks are:

• A competing approved Xe-133 supplier.
• A hospital switching to technetium-99m ventilation imaging.
• Better availability of alternative radiopharmaceuticals.
• A new closed-system device that makes a competing product easier to use.
• Manufacturing interruptions caused by reactor, purification, or transport constraints.
• Reduced demand from CT, MRI, or non-nuclear diagnostic pathways.

A Paragraph IV challenge could theoretically target listed patents for a formulation, method, device-linked drug product, or manufacturing process. In practice, the attractiveness of such litigation depends on the existence of commercially material, unexpired patents and the size of the Xe-133 market. The age of the product and limited conventional formulation complexity reduce the likelihood that broad drug patents would create a major litigation barrier.

What licensing opportunities exist for Xe-133?

Licensing opportunities are more likely to involve technology platforms than the isotope itself.

Potential transactions include:

• Regional distribution rights.
• Supply agreements with isotope producers.
• Exclusive rights to a closed inhalation system.
• Co-development of shielded single-use administration kits.
• Hospital-network contracts.
• Licensing of dose-calculation and radiation-safety software.
• Combination agreements linking Xe-133 with imaging equipment.

A strong licensing package would need to demonstrate measurable reductions in staff exposure, procedure time, gas loss, failed studies, or compliance costs. A claim to a new excipient without corresponding workflow or clinical benefit would likely have limited negotiating value.

How strong is the patent estate for Xenon Xe-133?

The underlying patent estate is likely weaker than the estate for a modern branded drug because:

• Xenon-133 is a mature radioactive isotope.
• The molecule has no meaningful new chemical entity pathway.
• The product has few conventional excipients.
• Pulmonary ventilation imaging is an established use.
• Competing technologies are available.

The strongest protection is likely to come from a layered platform covering packaging, delivery hardware, scavenging, calibration, manufacturing, and validated clinical workflows. Such protection can support commercial differentiation even when the active ingredient itself has little exclusivity value.

Key Takeaways

• Xe-133 is an inhaled diagnostic radiopharmaceutical, not a conventional excipient-dependent drug.
• Traditional excipient innovation has limited commercial value for this product.
• Carrier-gas composition, packaging, container closure, and delivery hardware are the most relevant formulation-adjacent opportunities.
• Closed-system administration, scavenging, dose calibration, and single-use kits offer stronger commercial potential than a new excipient.
• The principal barriers to entry are isotope production, radioactive-material licensing, decay-sensitive logistics, quality control, and hospital workflow integration.
• Patent value is more likely to reside in devices, manufacturing, packaging, and methods of use than in the Xe-133 composition.
• Competitive pressure comes from technetium-99m ventilation products, krypton-81m where available, CT, MRI, and pulmonary-function testing.
• Paragraph IV and Orange Book issues should be evaluated against current listed patents, but mature-product competition is more likely to arise through supply, workflow, and alternative imaging technologies.

Frequently Asked Questions

Can a new excipient extend Xenon Xe-133 exclusivity?

Usually not. A new excipient would need to produce a specific, clinically or operationally meaningful benefit and would more likely support a narrow formulation or device claim than broad product exclusivity.

Is Xenon Xe-133 a biologic requiring biosimilar analysis?

No. Xe-133 is a radioactive isotope drug. Biosimilar pathways apply to biological products, not to this type of diagnostic radiopharmaceutical.

Can Xe-133 be protected through a method-of-use patent?

Yes, a narrowly defined imaging protocol may be patentable if it satisfies novelty, nonobviousness, written-description, and enablement requirements. The commercial scope would depend on whether the protocol is routinely used and enforceable against clinical providers.

What is the main supply-chain risk for Xenon Xe-133?

Radioactive decay during production, shipment, and scheduling is the primary structural risk. Delays reduce usable activity and can make inventory economically impractical.

Are Xe-133 administration devices more valuable than excipient patents?

In most cases, yes. A device that improves containment, dose delivery, staff safety, or procedure throughput can address measurable hospital costs and provide stronger commercial differentiation than a conventional carrier-gas formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Xenon Xe-133 gas prescribing information. FDA-approved product labeling.

2. U.S. Nuclear Regulatory Commission. (n.d.). Medical use of radioactive materials. U.S. Nuclear Regulatory Commission.

3. U.S. Pharmacopeia. (n.d.). Xenon Xe 133. In United States Pharmacopeia and National Formulary.

4. International Atomic Energy Agency. (n.d.). Radiopharmaceutical production and quality control guidance. International Atomic Energy Agency.